ASO Author Reflections: Beyond the Binary: Using IHC Status to Predict Response to Neoadjuvant Therapy in HER2+ Early-Stage Breast Cancer

被引：0
|
作者：
Leah K. Winer [1 ]
Austin D. Williams [2 ]
机构：
[1] University of Kentucky,Division of Surgical Oncology, Department of Surgery
[2] Fox Chase Cancer Center,Division of Breast Surgery, Department of Surgical Oncology
来源：
Annals of Surgical Oncology | 2025年 / 32卷 / 2期
关键词：
D O I：
10.1245/s10434-024-16606-w
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：967 / 968
页数：1
相关论文
共 50 条
  • [41] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [42] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
    Agostinetto, Elisa
    de Azambuja, Evandro
    Lambertini, Matteo
    NPJ BREAST CANCER, 2023, 9 (01)
  • [44] Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
    Elisa Agostinetto
    Evandro de Azambuja
    Matteo Lambertini
    npj Breast Cancer, 9
  • [45] Author Correction: Deep learning radiomics can predict axillary lymph node status in early-stage breast cancer
    Xueyi Zheng
    Zhao Yao
    Yini Huang
    Yanyan Yu
    Yun Wang
    Yubo Liu
    Rushuang Mao
    Fei Li
    Yang Xiao
    Yuanyuan Wang
    Yixin Hu
    Jinhua Yu
    Jianhua Zhou
    Nature Communications, 12
  • [46] Using neoadjuvant therapy response to guide adjuvant therapy in HER2+breast cancer
    Krop, I.
    BREAST, 2019, 44 : S13 - S13
  • [47] Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
    Sanfeliu, Esther
    Braso-Maristany, Fara
    Dieci, Maria Vittoria
    Marin-Aguilera, Mercedes
    Gonzalez-Farre, Blanca
    Griguolo, Gaia
    Pascual, Tomas
    Galvan, Patricia
    Angelats, Laura
    Castillo, Oleguer
    Blasco, Paula
    Sirenko, Valeria
    Jares, Pedro
    Puig-Butille, Joan Anton
    Pare, Laia
    Martinez, Antonio
    Llombart-Cussac, Antonio
    Cortes, Javier
    Vivancos, Ana
    Villagrasa, Patricia
    Parker, Joel S.
    Perou, Charles M.
    Prat, Aleix
    Conte, PierFranco
    Guarneri, Valentina
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Implications of HER2-Targeted Therapy on Extent of Surgery for Early-Stage Breast Cancer
    Aziz, Hamza
    Marcom, P. Kelly
    Hwang, E. Shelley
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (05) : 1404 - 1405
  • [49] Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
    J Sun
    S Chia
    British Journal of Cancer, 2017, 116 : 4 - 9
  • [50] Implications of HER2-Targeted Therapy on Extent of Surgery for Early-Stage Breast Cancer
    Hamza Aziz
    P. Kelly Marcom
    E. Shelley Hwang
    Annals of Surgical Oncology, 2015, 22 : 1404 - 1405
12345